eFFECTOR Therapeutics (EFTR): Aggregate Business Value

Despite the absolute independence of biotech demand from macroeconomic cycles, eFFECTOR Therapeutics (EFTR) ceased operations and liquidated its assets following failed drug trials in mid-2024. This chart on the GURU.Markets platform shows the enterprise value at . Currently, business development is being hindered by geopolitical risks, which are blocking international logistics and the conduct of global clinical trials.

EFTR (eEFFECTOR Therapeutics, Inc.) Total Company Value history from 07/04/2022 to 10/27/2026

EFTR (eFFECTOR Therapeutics): analytical breakdowns and indicator data

- price and consensus price forecast:

Quote Chart eEFFECTOR Therapeutics, Inc.|EFTR - Consensus Target

- market capitalization data:

Market Value eEFFECTOR Therapeutics|EFTR - Total Company Value

- book capitalization data:

Accounting Value of a Share eEFFECTOR Therapeutics|EFTR - Company Book Value|Market Value to Book Value Ratio effector.com|EFTR - Cumulative Company Assets

- debt and liquidity data:

Total Debt to Capital eFFECTOR Therapeutics|EFTR - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio effector.com|EFTR - Company Aggregate Debts|Debt to Net Assets eEFFECTOR Therapeutics

Summary company analysis:eEFFECTOR Therapeutics, Inc. (EFTR)

Manufactured products of eEFFECTOR Therapeutics, Inc.

For a conservative investor, the aggregate valuation of eFFECTOR Therapeutics (EFTR) assets, calculated as the sum of market capitalization and net debt, serves as an objective measure of the cost of a full business acquisition. In the case of eFFECTOR Therapeutics (EFTR), this indicator reflects the real cost of ownership for a unique scientific protein translation platform, which retains leading biochemists through intellectual capital and stock option programs, thereby determining the issuer's long-term investment attractiveness.

Competing companies

AVBP - Full Business Value|Real Price to Acquire Entire Company Lantern LTRN|BIAF: Aggregate Business Value